Tag: Pfizer

10/18/2017

Why not discuss cost in news of new breast cancer drug approval?

2/6/2014

Journalism via news release as Pfizer gets free publicity without releasing any data

10/31/2012

More Pfizer Pfun

9/16/2011

Journalists weigh in on Pfizer-pfunded & other pharma-phunded journalism “events”

6/6/2011

Drug companies court bioethicists & lawyers

4/21/2011

Pfizer’s $100,000 Fellowships in Bioethics – a bioethicist’s view

Blog

Opinions on other issues in news, journals, PR, advertising, marketing

@HealthNewsRevu

Retweet on Twitter HealthNewsReview.org Retweeted

National Breast Cancer Coalition @NBCCStopBC·

A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold

Reply on Twitter 1520768892888567810 Retweet on Twitter 15207688928885678101 Like on Twitter 15207688928885678103 Twitter 1520768892888567810

HealthNewsReview.org @HealthNewsRevu·

Take all the issues enmeshed in any cancer screening story and amplify it with the liquid biopsy issue. @AP's ⁦@CarlaKJohnson⁩. did a solid job here. https://apnews.com/article/science-business-health-hodgkin-lymphoma-oregon-ca899bb9c4c7f1859d4e9ce16a1cf78d

Reply on Twitter 1516522980385472513 Retweet on Twitter 1516522980385472513 Like on Twitter 15165229803854725134 Twitter 1516522980385472513

HealthNewsReview.org @HealthNewsRevu·

Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/

Reply on Twitter 1506684595651035136 Retweet on Twitter 15066845956510351361 Like on Twitter 15066845956510351366 Twitter 1506684595651035136